STAT+: Pharmalitte: We’re reading about a Huntington’s gene therapy success, a low-cost HIV drug, and more

Good morning, this is Allison, substituting for Mr. Pharmalot. We may have three months left in the year, but I’m already starting to think about 2026, thanks to a handful of concert announcements and ticket sales opening up over the last week or so. Top of my list? British singer RAYE. And now, on to the news. …

An experimental gene therapy from Uniqure slowed the progression of Huntington’s disease by 75% after three years — study results reported Wednesday that are likely to support the first approval of a genetic treatment for the rare neurodegenerative condition, STAT reports. Uniqure plans to submit AMT-130 to the U.S. Food and Drug Administration in the first quarter of next year.

U.K. Health Secretary Wes Streeting told British patients to ignore Donald Trump’s call for pregnant women to avoid Tylenol, known in Britain as paracetamol, in a rare instance of a British minister overtly criticizing the U.S. president, Bloomberg relays. At a White House event Monday, Trump linked acetaminophen, the active ingredient in Tylenol, to autism, encouraging women to tough out fevers without resorting to the painkiller. The U.K.’s medicines regulator, known as the MHRA, warned that listening to Trump’s advice could harm unborn babies.

Continue to STAT+ to read the full story…